Lung Cancer is one of the most common cancers and according to the American Cancer Society; it is by far the leading cause of cancer deaths. August 1 is observed as World…
Category: Lung Cancer News
High Lung Cancer Risk among Smokers for Whom Screening is not Recommended
According to the research paper published in the Journal of the American Medical Association (JAMA) Oncology, some current and former older smokers who are not recommended for screening are at high risk…
Study finds Biomarker in Liquid Biopsy for Lung Cancer Appears Accurate in Predicting Immunotherapy Response
The researchers at Mount Sinai have found that a simple blood test called liquid biopsy could be a better indicator of whether cancer immunotherapy will be successful for lung cancer patients than…
Imaging Approach to Detect Lung Cancer Earlier, Study Reveals
Lung cancer is the third most common type of cancers in the United States, according to the Cancers for Disease Control and Prevention. A new study has found a new way for…
Moffitt Researchers Find New Target for CAR T Cells in Solid Tumors
The researchers from Moffitt Cancer Center in Tampa, Florida have published results identifying the potential target for Chimeric Antigen Receptor (CAR) T-cell therapies in solid tumors. The findings have been published in…
Emphysema on Computed Tomography – Associated with Increased Risk of Lung Cancer
Lung cancer is responsible for cancer-related deaths worldwide. Continuous research and studies are being carried out to reduce its risk. According to a new study published in Radiology, Computed Tomography detected emphysema is…
Study Suggests Why Some Tobacco Smokers Don’t Get Lung Cancer
One of the major causes behind lung cancer remains smoking, yet only a minority of smokers develops this disease. A new study has been led by scientists at Albert Einstein College of…
FDA Approves Nivolumab Plus Chemo as Neoadjuvant Therapy for NSCLC Treatment
The FDA has approved nivolumab plus platinum-doublet chemotherapy for patients with non-small cell lung cancer in the neoadjuvant setting. Nivolumab is the first immune checkpoint inhibitor to get approval for resectable NSCLC….